| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10046013 | HBV | ENSG00000075043.21 | protein_coding | KCNQ2 | No | No | 3785 | O43526 Q53Y30 |
| TVIS10042508 | HBV | ENSG00000075043.21 | protein_coding | KCNQ2 | No | No | 3785 | O43526 Q53Y30 |
| TVIS30080395 | HIV | ENSG00000075043.21 | protein_coding | KCNQ2 | No | No | 3785 | O43526 Q53Y30 |
| TVIS20021777 | HPV | ENSG00000075043.21 | protein_coding | KCNQ2 | No | No | 3785 | O43526 Q53Y30 |
| TVIS20055859 | HPV | ENSG00000075043.21 | protein_coding | KCNQ2 | No | No | 3785 | O43526 Q53Y30 |
| TVIS44021418 | HTLV-1 | ENSG00000075043.21 | protein_coding | KCNQ2 | No | No | 3785 | O43526 Q53Y30 |
| TVIS44042652 | HTLV-1 | ENSG00000075043.21 | protein_coding | KCNQ2 | No | No | 3785 | O43526 Q53Y30 |
| TVIS44042713 | HTLV-1 | ENSG00000075043.21 | protein_coding | KCNQ2 | No | No | 3785 | O43526 Q53Y30 |
| TVIS44042733 | HTLV-1 | ENSG00000075043.21 | protein_coding | KCNQ2 | No | No | 3785 | O43526 Q53Y30 |
| TVIS44042732 | HTLV-1 | ENSG00000075043.21 | protein_coding | KCNQ2 | No | No | 3785 | O43526 Q53Y30 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | KCNQ2 |
|---|---|
| DrugBank ID | DB04953 |
| Drug Name | Ezogabine |
| Target ID | BE0000897 |
| UniProt ID | O43526 |
| Regulation Type | |
| PubMed IDs | 15662042; 17184917; 17456683; 10908292; 10953053 |
| Citations | Wuttke TV, Seebohm G, Bail S, Maljevic S, Lerche H: The new anticonvulsant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate. Mol Pharmacol. 2005 Apr;67(4):1009-17. Epub 2005 Jan 20.@@Hirano K, Kuratani K, Fujiyoshi M, Tashiro N, Hayashi E, Kinoshita M: Kv7.2-7.5 voltage-gated potassium channel (KCNQ2-5) opener, retigabine, reduces capsaicin-induced visceral pain in mice. Neurosci Lett. 2007 Feb 14;413(2):159-62. Epub 2006 Dec 20.@@Punke MA, Friederich P: Amitriptyline is a potent blocker of human Kv1.1 and Kv7.2/7.3 channels. Anesth Analg. 2007 May;104(5):1256-64, tables of contents.@@Main MJ, Cryan JE, Dupere JR, Cox B, Clare JJ, Burbidge SA: Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine. Mol Pharmacol. 2000 Aug;58(2):253-62.@@Wickenden AD, Yu W, Zou A, Jegla T, Wagoner PK: Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels. Mol Pharmacol. 2000 Sep;58(3):591-600. |
| Groups | Approved; Investigational |
| Direct Classification | Phenylbenzamines |
| SMILES | CCOC(=O)NC1=C(N)C=C(NCC2=CC=C(F)C=C2)C=C1 |
| Pathways | |
| PharmGKB | PA144997862 |
| ChEMBL | CHEMBL41355 |
